.Merck beats revenues assumptions, rears sales expectation on sturdy demand for leading drugs like Keytruda CNBCMerck & Co. (MRK US) Beats Revenue Forecasts as Keytruda Purchases Surge BloombergMerck Sell: Pharma Titan Posts Tough Outcomes, However Outlook Drops Short Real estate investor's Business DailyMerck Announces Second-Quarter 2024 Financial Results Yahoo FinanceMerck beats revenue as well as purchases assumptions amid Keytruda advantage, but provides mixed full-year expectation MarketWatch.